CliffBio
biologic

Xolair

omalizumab

Loss of exclusivitySeptember 2030projected — 12-year biologic exclusivity estimate
CompanyGenentech →View the full company profile on CliffBio

Drug detail

Brand nameXolair
Active ingredientomalizumab
Strength75MG/0.5ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalSeptember 2018
Marketing statusRx

More from Genentech

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Xolair patent cliff — loss of exclusivity September 2030 | CliffBio